SSI(SZ:002742)2025-08-26 11:15Financial Performance - The company's operating revenue for the reporting period was ¥486,347,592.22, a decrease of 33.89% compared to ¥735,672,725.36 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was -¥130,978,549.31, representing a decline of 97.02% from -¥66,479,955.50 year-on-year[19]. - The net cash flow from operating activities improved to ¥7,150,445.12, a significant increase of 140.78% compared to -¥17,532,460.82 in the previous year[19]. - The total assets at the end of the reporting period were ¥2,476,505,058.57, down 5.69% from ¥2,626,041,333.84 at the end of the previous year[19]. - The company reported a weighted average return on net assets of 27.24%, an increase of 48.69% compared to -21.45% in the same period last year[19]. - The net profit after deducting non-recurring gains and losses was -¥126,905,323.60, a decrease of 136.51% from -¥53,657,306.43 in the previous year[19]. - The company’s net assets attributable to shareholders decreased to -¥549,825,152.76, a decline of 33.51% from -¥411,810,939.89 at the end of the previous year[19]. - The company reported a net cash increase of ¥-6,966,388.53, which was an improvement of 77.42% compared to ¥-30,856,156.07 from the previous period[35]. - The company reported a significant increase in other payables from CNY 266,471,526.78 to CNY 342,862,589.74, an increase of about 28.6%[145]. - The company reported a gross profit margin of approximately -24% for the current period, compared to -3.3% in the previous period[152]. Business Segments - The construction materials and chemical segment remains the main business, with a focus on ready-mixed concrete and additives, although market demand has sharply declined[26]. - The pharmaceutical manufacturing segment includes intermediates, active pharmaceutical ingredients (APIs), and formulation products, with key intermediates like procaine hydrochloride and chloramphenicol holding leading market positions[27]. - The pharmaceutical segment accounted for 59.77% of total revenue, generating ¥290,705,551.09, despite a 20.68% decline year-over-year[37]. - The construction materials and chemicals segment saw a significant drop in revenue, contributing only 39.94% with ¥194,239,128.52, down 46.02% from the previous year[37]. - The company has diversified into pharmaceutical manufacturing, reducing operational risks associated with macroeconomic cycles, and enhancing profitability through strategic management adjustments[28]. - The company is one of the largest producers of concrete additives in Southwest China, offering a wide range of customized solutions to meet diverse market needs[31]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares for this period[4]. - The company plans to implement a diversification and internationalization strategy to mitigate risks associated with the declining construction materials industry[52]. - The company has formed a dual-driven business model of "building materials + pharmaceutical manufacturing," effectively mitigating raw material market fluctuations and optimizing resource sharing[33]. - The company is strategically located in Chongqing, benefiting from its designation as a national important central city and a key point in the "Belt and Road" initiative, which is expected to drive future growth opportunities[33]. - The company emphasizes technological research and development, establishing a research center for concrete additives and pharmaceuticals to support its production and operational needs[29]. - The company has established a comprehensive drug research and development system, focusing on antibiotics, digestive, respiratory, endocrine, and cardiovascular drugs, with a robust pipeline for antiviral and diabetes medications[30]. Legal and Compliance Issues - The company is facing significant financial pressure and has applied for bankruptcy reorganization, which has been accepted by the court[53]. - The company is actively managing its legal risks and disputes to minimize financial impact[66]. - The company is involved in a second-instance trial for a dispute valued at 89.06 million CNY, with no liability recognized[66]. - The company has reached mediation agreements in several cases, with payments pending from the opposing parties[67]. - The company has not reported any non-compliance issues regarding external guarantees during the reporting period[62]. - The company has no significant related party transactions during the reporting period[72]. Shareholder Information - The total number of shares outstanding is 432,000,000, with 100% being unrestricted shares[131]. - The largest shareholder, Pan Xianwen, holds 17.26% of the shares, totaling 74,554,232 shares, which are currently frozen[132]. - The company has a total of 11,319 shareholders at the end of the reporting period[132]. - The number of unrestricted shares is 431,858,082, representing 99.97% of total shares[130]. - The company does not have any ongoing share repurchase programs or significant changes in shareholding structure reported[131]. Financial Liabilities and Guarantees - The company has a total outstanding principal of RMB 44,200.00 million as of June 30, 2025[98]. - The company has not repaid the principal amount of RMB 772.12 million owed to Agricultural Bank of China as of June 30, 2025[101]. - The total guarantee amount for the company (sum of the three major items) is CNY 298.51 billion, with a total actual guarantee amount of CNY 259.12 billion[87]. - The company has pledged 100% equity of Liaoyuan Baikang Pharmaceutical Co. for a loan of CNY 64 million, which is overdue[125]. - The company has entered a forced execution phase for loans totaling CNY 64 million due to financial difficulties[115]. Future Outlook - The company plans to explore potential mergers and acquisitions to strengthen its market presence[171]. - Future guidance suggests a conservative growth outlook, with expected revenue growth of approximately 5% in the next quarter[167]. - The company has set a revenue guidance of 1.5 billion yuan for the next fiscal year, aiming for a growth rate of approximately 20%[171]. - The company plans to expand its market presence through strategic partnerships and new product launches in the upcoming quarters[171].